These funds are earmarked for finalizing the OST-HER2 osteosarcoma trial payments, manufacturing for FDA approval, and other operational costs, including the commercialization of the product.

A deeper understanding of osteosarcoma, the most common primary malignant bone tumor affecting children and adolescents, is reshaping strategies for overcoming treatment resistance. Central to ...

Osteosarcoma is a type of bone cancer that originates in the cells that form an individual's bones. In rare cases, it may ...

(RTTNews) - OS Therapies Inc. (OSTX) Thursday announced positive data for OST-HER2 in combination with palliative radiation in dogs with unresected appendicular osteosarcoma. Results from the ...